Report cover image

Prescription Drugs Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Oct 01, 2024
Length 140 Pages
SKU # FOB19224264

Description

Prescription Drugs Market



Growth Factors of Prescription Drugs Market

The global prescription drugs market size was valued at USD 1162.61 billion in 2023 and is projected to grow from USD 1,240.33 billion in 2024 to USD 2,151.63 billion by 2032, exhibiting a CAGR of 7.1% during the forecast period of 2024-2032.

The COVID-19 pandemic disrupted supply chains and delayed scientific trials in the Prescription Drugs Market, main to shortages of raw substances. Conversely, it heightened the call for medicinal drugs associated with breathing situations, antivirals, and vaccines, even as increasing authorities' consciousness on healthcare contributed to the marketplace boom, impeding the prescription drugs market growth.

The Prescription Drugs Market is ordinarily driven by the growing prevalence of continual diseases, an aging populace, and heightened healthcare spending. Innovations in pharmaceutical studies, a focal point on personalized medicine, and a developing call for strong point tablets and biologics also contribute to market growth, supported through favorable regulatory frameworks.

As a sub-sector of prescription drugs, the rising of customization through genetic and other features of an individual patient is seen to be a new trend. Genetic testing prescribes populations that may require particular therapies or will be endangered by definite pathologies, broadening the prescription drugs share worldwide. These details are then used to choose the correct medication and treatment procedures. Moreover, such treatment strategies as molecular targeted therapy are being adopted for effective molecular targets of diseases that define more effective treatment plans.

Comprehensive Analysis of Prescription Drugs Market

The prescription drug market is segmented by product type, remedy, and distribution channel. In product types, other prescription drugs dominate due to rising prescriptions for continual situations, with orphan tablets expected to grow quicker due to accelerated scientific trials and approvals. The oncology remedy segment leads the marketplace, fueled by rising cancer prevalence and new-centered cures. Additionally, health center pharmacies are the number one distribution channel, providing vital therapeutics requiring professional management, while online pharmacies are anticipated to develop hastily because of their convenience.

The North America region led the prescription drugs market by benefitting a size of USD 576.35 billion in 2023 due to the high incidence of various continual illnesses in the area, the North America pharmaceuticals market has experienced dominance.

The leading prescription drug market players significantly shape its growth trajectory and establish industry standards. Key companies such as Novartis AG (Switzerland), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), Merck & Co., Inc. (U.S.), AbbVie, Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca (U.K.), and CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY) (U.S.) contribute to a competitive landscape, driving innovation and advancements in the market.

In October 2023, Novartis AG identified that strategies to demerge Sandoz, generics, and biosimilar divisions enabled you to move to an organization based on new-age medicine.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 7.1% from 2024-2032

Unit Value (USD billion)

Segmentation By Product Type
  • Generics
  • Orphan
  • Other Prescription Drugs
By Application
  • Oncology
  • Central Nervous System
  • Vaccines
  • Immunosuppressants
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others
By Geography
  • North America (By Product Type, By Application, By Distribution Channel, and By Country)
  • U.S.
  • Canada
  • Europe (By Product Type, By Diabetes Type, By Distribution Channel, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
  • Latin America (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

140 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Prevalence of Key Diseases - By Key Countries/ Region, 2023
4.2. Pipeline Analysis, By Key Players
4.3. Key Industry Developments, By Key Players
4.4. Regulatory Scenario, By Key Regions
4.5. New Product Launches, By Key Players
4.6. Impact of COVID-19 on the Market
5. Global Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Product Type
5.1.1. Generics
5.1.2. Orphan
5.1.3. Other Prescription Drugs
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1. Oncology
5.2.2. Central Nervous System
5.2.3. Vaccines
5.2.4. Immunosuppressants
5.2.5. Others
5.3. Market Analysis, Insights and Forecast – By Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies & Drug Stores
5.3.3. Online Pharmacies
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Product Type
6.1.1. Generics
6.1.2. Orphan
6.1.3. Other Prescription Drugs
6.2. Market Analysis, Insights and Forecast – By Application
6.2.1. Oncology
6.2.2. Central Nervous System
6.2.3. Vaccines
6.2.4. Immunosuppressants
6.2.5. Others
6.3. Market Analysis, Insights and Forecast – By Distribution Channel
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies & Drug Stores
6.3.3. Online Pharmacies
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Product Type
7.1.1. Generics
7.1.2. Orphan
7.1.3. Other Prescription Drugs
7.2. Market Analysis, Insights and Forecast – By Application
7.2.1. Oncology
7.2.2. Central Nervous System
7.2.3. Vaccines
7.2.4. Immunosuppressants
7.2.5. Others
7.3. Market Analysis, Insights and Forecast – By Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies & Drug Stores
7.3.3. Online Pharmacies
7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Rest of Europe
8. Asia Pacific Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Product Type
8.1.1. Generics
8.1.2. Orphan
8.1.3. Other Prescription Drugs
8.2. Market Analysis, Insights and Forecast – By Application
8.2.1. Oncology
8.2.2. Central Nervous System
8.2.3. Vaccines
8.2.4. Immunosuppressants
8.2.5. Others
8.3. Market Analysis, Insights and Forecast – By Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies & Drug Stores
8.3.3. Online Pharmacies
8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
9. Latin America Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Product Type
9.1.1. Generics
9.1.2. Orphan
9.1.3. Other Prescription Drugs
9.2. Market Analysis, Insights and Forecast – By Application
9.2.1. Oncology
9.2.2. Central Nervous System
9.2.3. Vaccines
9.2.4. Immunosuppressants
9.2.5. Others
9.3. Market Analysis, Insights and Forecast – By Distribution Channel
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies & Drug Stores
9.3.3. Online Pharmacies
9.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
10. Middle East & Africa Prescription Drugs Market Analysis, Insights and Forecast, 2019-2032
10.1. Market Analysis, Insights and Forecast – By Product Type
10.1.1. Generics
10.1.2. Orphan
10.1.3. Other Prescription Drugs
10.2. Market Analysis, Insights and Forecast – By Application
10.2.1. Oncology
10.2.2. Central Nervous System
10.2.3. Vaccines
10.2.4. Immunosuppressants
10.2.5. Others
10.3. Market Analysis, Insights and Forecast – By Distribution Channel
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies & Drug Stores
10.3.3. Online Pharmacies
10.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
10.4.1. GCC
10.4.2. South Africa
10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Global Market Share Analysis (2023)
11.2. Company Profiles
11.2.1. Novartis AG
11.2.1.1. Overview
11.2.1.2. Products & Services
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. Pfizer, Inc.
11.2.2.1. Overview
11.2.2.2. Products & Services
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. F. Hoffmann-La Roche Ltd.
11.2.3.1. Overview
11.2.3.2. Products & Services
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Strategies
11.2.3.6. Financials (Based on Availability)
11.2.4. Sanofi
11.2.4.1. Overview
11.2.4.2. Products & Services
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. Johnson & Johnson Services, Inc.
11.2.5.1. Overview
11.2.5.2. Products & Services
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. Merck & Co., Inc.
11.2.6.1. Overview
11.2.6.2. Products & Services
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. AbbVie, Inc.
11.2.7.1. Overview
11.2.7.2. Products & Services
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. GlaxoSmithKline plc.
11.2.8.1. Overview
11.2.8.2. Products & Services
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. AstraZeneca
11.2.9.1. Overview
11.2.9.2. Products & Services
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)
11.2.10. CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY)
11.2.10.1. Overview
11.2.10.2. Products & Services
11.2.10.3. SWOT Analysis
11.2.10.4. Recent Developments
11.2.10.5. Strategies
11.2.10.6. Financials (Based on Availability)
12.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us